Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors

Romidepsin (FK228, depsipeptide) is a potent histone deacetylase (HDAC) inhibitor that has FDA approval for the treatment of cutaneous and peripheral T‐cell lymphomas. We have previously reported that FK228 and its analogs have an additional activity as phosphatidylinositol 3‐kinase (PI3K) inhibitor...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2015-02, Vol.106 (2), p.208-215
Main Authors: Saijo, Ken, Imamura, Jin, Narita, Koichi, Oda, Akifumi, Shimodaira, Hideki, Katoh, Tadashi, Ishioka, Chikashi
Format: Article
Language:English
Subjects:
Adenosine Triphosphate - metabolism
Apoptosis - drug effects
Cell Line, Tumor
Cell Proliferation - drug effects
Depsipeptides - pharmacology
Drug development
dual inhibitor
Enzyme Inhibitors - pharmacology
HCT116 Cells
HDAC
Histone Deacetylase Inhibitors - pharmacology
Histone Deacetylases - metabolism
Humans
Original
Phosphatidylinositol 3-Kinases - antagonists & inhibitors
Phosphorylation - drug effects
PI3K
romidepsin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Romidepsin (FK228, depsipeptide) is a potent histone deacetylase (HDAC) inhibitor that has FDA approval for the treatment of cutaneous and peripheral T‐cell lymphomas. We have previously reported that FK228 and its analogs have an additional activity as phosphatidylinositol 3‐kinase (PI3K) inhibitors, and are defined as HDAC/PI3K dual inhibitors. Because a combination of an HDAC inhibitor and a PI3K inhibitor induces apoptosis in human cancer cells in a synergistic manner, development of an HDAC/PI3K dual inhibitor will provide an attractive novel drug for cancer therapy. Using structure‐based optimization of the analogs, FK‐A11 was identified as the most potent analog. FK‐A11 inhibited phosphorylation of AKT and accelerated histone acetylation at lower concentrations, resulting in stronger cytotoxic effects than FK228 and the other analogs in human cancer cells. In this study, we have characterized the biochemical, biological and structural properties of FK228 analogs as PI3K inhibitors. First, FK‐A11 is an ATP competitive PI3K inhibitor. Second, FK‐A11 is a pan‐p110 isoform inhibitor. Third, FK‐A11 selectively inhibits PI3K among 22 common cellular kinases. Fourth, conformational changes of FK228 analogs by reduction of an internal disulfide bond have no effect on PI3K inhibitory activity, unlike HDAC inhibitory activity. Finally, molecular modeling of PI3K‐FK228 analogs and analyses of the binding affinities identified the structure that defines potency for PI3K inhibitory activity. These results prove our concept that a series of FK228 analogs are HDAC/PI3K dual inhibitors. These findings should help in the development of FK228 analogs as novel HDAC/PI3K dual inhibitors. FK228 and its analogs have been defined as HDAC/PI3K dual inhibitors. This study identified the novel analog, FK‐A11 as the most potent inhibitor, and demonstrated the biochemical, biological, and structural properties as HDAC/PI3K dual inhibitors.
ISSN:1347-9032
1349-7006
DOI:10.1111/cas.12585